Thomas Norton, MD
Ophthalmology · Alexandria, LANPI 1801856232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Alcon at 43.3% of the total. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $45.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Glaukos Corporation$1K
- AbbVie$566
- Sight Sciences, Inc.$413
- Johnson & Johnson Surgical Vision, Inc.$306
- Mallinckrodt Hospital Products Inc.$298
- plus $2K from 24 others
What the payments were for
- Food & beverage$8,26097%
- Education$2002%
- Entertainment$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 62 | $3,674 |
| Glaukos Corporation | 14 | $1,327 |
| AbbVie(2 entities) | 18 | $566 |
| Sight Sciences, Inc. | 14 | $413 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $306 |
| Mallinckrodt Hospital Products Inc. | 7 | $298 |
| Biotissue Holdings Inc. | 4 | $259 |
| Ivantis, Inc | 2 | $225 |
| Genentech USA, Inc. | 4 | $180 |
| Rxsight Inc | 5 | $177 |
| Aerie Pharmaceuticals, Inc. | 3 | $156 |
| Sun Pharmaceutical Industries Inc. | 7 | $140 |
| Ocular Therapeutix, Inc. | 9 | $133 |
| Oyster Point Pharma, Inc. | 5 | $95 |
| Amgen(2 entities) | 4 | $70 |
| Bausch & Lomb Americas Inc. | 3 | $58 |
| Iridex Corporation | 1 | $53 |
| Merz Pharmaceuticals, LLC | 2 | $50 |
| Omeros Corporation | 3 | $40 |
| Rayner Intraocular Lenses Limited | 2 | $37 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Novartis | 2 | $25 |
| Shire North American Group Inc | 1 | $25 |
| Eyepoint US, Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Nova Eye, Inc. | 1 | $22 |
| Dompe US, Inc. | 1 | $21 |
| Biogen | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$626
- ARGOS$513
- iStent inject W$377
- Hydrus Microstent$255
- Hydrus$225
- iStent Trabecular Micro-Bypass System Model iS3$173
- Prokera$171
- AmnioGraft$171
- iDoseTR$167
- iDose$142
- AcrySof IQ VIVITY IOL$134
- KXL System$129
- Photrexa$129
- Rhopressa$125
- Rocklatan$125
- Tecnis Toric 1-piece IOL$124
- Whitestar Phacoemulsficiation System$124
- Catalys Laser System$124
- ORA System VerifEye$124
- iStent inject Trabecular Micro-Bypass Stent System$123
How this compares
$8,482 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 206 | $76,709 |
| Prednisolone Acetate | 718 | $36,409 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $14,262 |
| MoxifloxacinMoxifloxacin Hcl | 711 | $14,177 |
| Ketorolac Tromethamine | 677 | $12,419 |
| RhopressaNetarsudil Mesylate | 21 | $12,068 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $10,248 |
| Timolol Maleate | 224 | $7,465 |
| Cyclosporine | 11 | $7,353 |
| Latanoprost | 567 | $6,934 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 104 | $5,166 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $4,075 |
| Travoprost | 19 | $3,670 |
| Brimonidine Tartrate | 60 | $3,580 |
| Brinzolamide | 12 | $3,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $566 | $86,958231 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $156 | $26,32957 claims |
| AlconSimbrinza | $3,674 | $4,07519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Alexandria
- Michael RedmondAlexandria$24K
- Eric ReishAlexandria$23K
- Patrick RedmondAlexandria$11K
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.